The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
Abstract
Purpose: The National Surgical Adjuvant Breast and Bowel Project Protocol B-27 was designed to determine the effect of adding docetaxel after four cycles of preoperative doxorubicin and cyclophosphamide (AC) on clinical and pathological response rates and on disease-free and overall survival of women with operable breast cancer. Patients and Methods: Women (N = 2,411) with operable primary breast cancer were randomly assigned to receive either four cycles of preoperative AC followed by surgery (group I), or four cycles of AC followed by four cycles of docetaxel, followed by surgery (group II), or four cycles of AC followed by surgery and then four cycles of docetaxel (group III). Clinical and pathologic tumor responses to preoperative therapy were assessed. Results: Mean tumor size (4.5 cm) and other key characteristics were evenly balanced among the three treatment arms. Grade 4 toxicity was observed in 10.3% of 2,400 patients during AC treatment, and in 23.4% of 1584 patients during docetaxel treatment. Compared to preoperative AC alone, preoperative AC followed by docetaxel increased the clinical complete response rate (40.1% v 63.6%; P < .001), the overall clinical response rate (85.5% v 90.7%; P < .001), the pathologic complete response rate (13.7% v 26.1%; P < .001), and the proportion of patients with negative nodes (50.8% v 58.2%; P < .001). Pathologic primary breast tumor response was a significant predictor of pathologic nodal status (P < .001). Conclusion: The addition of four cycles of preoperative docetaxel after four cycles of preoperative AC significantly increased clinical and pathologic response rates for operable breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Self-citationPolychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Kuerer, H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.460 · Cited by 1,330
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
van der Hage, J. A., van de Velde, C. J. H., Julien, J.-P., Tubiana-Hulin, M., Vandervelden, C., Duchateau, L., & Cooperating Investigators (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.22.4224 · Cited by 1,107
(2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.13.979 · Cited by 893
THE IMPACT OF NATIONAL CANCER ACT
(1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel
Smith, I. C., Heys, S. D., Hutcheon, A. W., Miller, I. D., Payne, S., Gilbert, F. J., Ah-See, A. K., Eremin, O., Walker, L. G., Sarkar, T. K., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1456 · Cited by 782
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobagyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 746
Cited by
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Self-citationvon Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789
“Preoperative therapy, initially used only for locally advanced breast cancer, has become more common for patients with operable disease.(1-17) This allows more individuals to undergo breast-conserving procedures and provides for observation of response to treatment.”
BackgroundSelf-citationNeoadjuvant Versus Adjuvant Systemic Treatment in Breast Cancer: A Meta-Analysis
Mauri, D., Pavlidis, N., & Ioannidis, J. P. A. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji021 · Cited by 1,200
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N., Hwang, E. S., Khan, S. A., Loibl, S., Morris, E. A., Perez, A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03399 · Cited by 1,040
Adjuvant Docetaxel for Node-Positive Breast Cancer
Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J.-P., Weaver, C., Tomiak, E., Al-Tweigeri, T., Chap, L., Juhos, E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043681 · Cited by 954
Bear, H. D., Anderson, S., Smith, R. E., Geyer, C. E., Mamounas, E. P., Fisher, B., Brown, A. M., Robidoux, A., Margolese, R., Kahlenberg, M. S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.1665 · Cited by 943
Self-citationOverview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
Kaufmann, M., Hortobagyi, G. N., Goldhirsch, A., Scholl, S., Makris, A., Valagussa, P., Blohmer, J.-U., Eiermann, W., Jackesz, R., Jonat, W., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6187 · Cited by 725
Self-citationHellmann, M. D., Chaft, J. E., William, W. N., Rusch, V., Pisters, K. M. W., Kalhor, N., Pataer, A., Travis, W. D., Swisher, S. G., & Kris, M. G. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70334-6 · Cited by 646
Guarneri, V., Broglio, K., Kau, S.-W., Cristofanilli, M., Buzdar, A. U., Valero, V., Buchholz, T., Meric, F., Middleton, L., Hortobagyi, G. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6914 · Cited by 601
Mamounas, E. P., Anderson, S. J., Dignam, J. J., Bear, H. D., Julian, T. B., Geyer, C. E., Taghian, A., Wickerham, D. L., & Wolmark, N. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.8369 · Cited by 587
Self-citationTanei, T., Morimoto, K., Shimazu, K., Kim, S. J., Tanji, Y., Taguchi, T., Tamaki, Y., & Noguchi, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1479 · Cited by 574
Mamounas, E. P., Brown, A., Anderson, S., Smith, R., Julian, T., Miller, B., Bear, H. D., Caldwell, C. B., Walker, A. P., Mikkelson, W. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.188 · Cited by 548
Self-citationVeronesi, U., Boyle, P., Goldhirsch, A., Orecchia, R., & Viale, G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66546-4 · Cited by 542
Taxanes, microtubules and chemoresistant breast cancer
McGrogan, B. T., Gilmartin, B., Carney, D. N., & McCann, A. (2008) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.10.004 · Cited by 535
Vogel, C. L., Wojtukiewicz, M. Z., Carroll, R. R., Tjulandin, S. A., Barajas-Figueroa, L. J., Wiens, B. L., Neumann, T. A., & Schwartzberg, L. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.102 · Cited by 482
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., Baez-Diaz, L., Brufsky, A. M., Mehta, R. S., Fehrenbacher, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111097 · Cited by 461
Self-citationDrug Combinations in Breast Cancer Therapy
Fisusi, F. A., & Akala, E. O. (2019) · Pharmaceutical Nanotechnology · doi:10.2174/2211738507666190122111224 · Cited by 449
MRI for breast cancer screening, diagnosis, and treatment
Morrow, M., Waters, J., & Morris, E. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61350-0 · Cited by 448
Boughey, J. C., McCall, L. M., Ballman, K. V., Mittendorf, E. A., Ahrendt, G. M., Wilke, L. G., Taback, B., Leitch, A. M., Flippo-Morton, T., & Hunt, K. K. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000924 · Cited by 440
Hennessy, B. T., Hortobagyi, G. N., Rouzier, R., Kuerer, H., Sneige, N., Buzdar, A. U., Kau, S. W., Fornage, B., Sahin, A., Broglio, K., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5023 · Cited by 420
Green, M. C., Buzdar, A. U., Smith, T., Ibrahim, N. K., Valero, V., Rosales, M. F., Cristofanilli, M., Booser, D. J., Pusztai, L., Rivera, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.232 · Cited by 419
von Minckwitz, G., Raab, G., Caputo, A., Schütte, M., Hilfrich, J., Blohmer, J. U., Gerber, B., Costa, S. D., Merkle, E., Eidtmann, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.078 · Cited by 417
Axillary Nodal Evaluation in Breast Cancer: State of the Art
Chang, J. M., Leung, J. W. T., Moy, L., Ha, S. M., & Moon, W. K. (2020) · Radiology · doi:10.1148/radiol.2020192534 · Cited by 387
Pierga, J.-Y., Bidard, F.-C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., de Cremoux, P., Salmon, R., Vincent-Salomon, A., & Marty, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0030 · Cited by 369
Anderson, B. O., Shyyan, R., Eniu, A., Smith, R. A., Yip, C.-H., Bese, N. S., Chow, L. W. C., Masood, S., Ramsey, S. D., & Carlson, R. W. (2006) · The Breast Journal · doi:10.1111/j.1075-122x.2006.00199.x · Cited by 359
Self-citationColleoni, M., Viale, G., Zahrieh, D., Pruneri, G., Gentilini, O., Veronesi, P., Gelber, R. D., Curigliano, G., Torrisi, R., Luini, A., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0380 · Cited by 353
Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents
Isakoff, S. J. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181d24ff7 · Cited by 348
Seo, A. N., Lee, H. J., Kim, E. J., Kim, H. J., Jang, M. H., Lee, H. E., Kim, Y. J., Kim, J. H., & Park, S. Y. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.634 · Cited by 317
Yankeelov, T. E., Lepage, M., Chakravarthy, A., Broome, E. E., Niermann, K. J., Kelley, M. C., Meszoely, I., Mayer, I. A., Herman, C. R., McManus, K., et al. (2007) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2006.09.006 · Cited by 314
Docetaxel for treatment of solid tumours: a systematic review of clinical data
Montero, A., Fossella, F., Hortobagyi, G., & Valero, V. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70094-2 · Cited by 311
Prediction of Docetaxel Response in Human Breast Cancer by Gene Expression Profiling
Iwao-Koizumi, K., Matoba, R., Ueno, N., Kim, S. J., Ando, A., Miyoshi, Y., Maeda, E., Noguchi, S., & Kato, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.078 · Cited by 309
Mazouni, C., Peintinger, F., Wan-Kau, S., Andre, F., Gonzalez-Angulo, A. M., Symmans, W. F., Meric-Bernstam, F., Valero, V., Hortobagyi, G. N., & Pusztai, L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2271 · Cited by 299
Past, Present, and Future Challenges in Breast Cancer Treatment
Sledge, G. W., Mamounas, E. P., Hortobagyi, G. N., Burstein, H. J., Goodwin, P. J., & Wolff, A. C. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4139 · Cited by 277
Self-citationAh-See, M.-L. W., Makris, A., Taylor, N. J., Harrison, M., Richman, P. I., Burcombe, R. J., Stirling, J. J., d'Arcy, J. A., Collins, D. J., Pittam, M. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4310 · Cited by 263
Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review
Pilewskie, M., & Morrow, M. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4163 · Cited by 262
Benson, J. R., Jatoi, I., Keisch, M., Esteva, F. J., Makris, A., & Jordan, V. C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60316-0 · Cited by 261
Pathological Complete Response in Neoadjuvant Treatment of Breast Cancer
Cortazar, P., & Geyer, C. E. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4404-8 · Cited by 252
Hurley, J., Doliny, P., Reis, I., Silva, O., Gomez-Fernandez, C., Velez, P., Pauletti, G., Powell, J. E., Pegram, M. D., & Slamon, D. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.8886 · Cited by 245
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy
Andre, F., & Pusztai, L. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0636 · Cited by 134
Gu, Y.-L., Pan, S.-M., Ren, J., Yang, Z.-X., & Jiang, G.-Q. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2016.12.010 · Cited by 128
Predictive factors for response to docetaxel in human breast cancers
Noguchi, S. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00265.x · Cited by 127
Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy
Fava, G. A., Tomba, E., & Tossani, E. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.10.014 · Cited by 41
Metadata
- Authors
- Bear, H. D., Anderson, S., Brown, A., Smith, R., Mamounas, E. P., Fisher, B., Margolese, R., Theoret, H., Soran, A., Wickerham, D. L., & Wolmark, N.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-11-15
- Volume
- 21
- Issue
- 22
- Pages
- 4165-4174
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162760540
- Cited by
- 1,118
- References
- 42
- FWCI
- 25.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.